Diabetic Macular Edema Treatments
|DIABETIC MACULAR EDEMA TREATMENTS|
|VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS|
|brolucizumab-dbll||Beovu||6mg/0.05mL||soln for intravitreal inj||6mg (0.05mL) every 6wks (approx. 39–45 days) for the 1st 5 doses, followed by 6mg (0.05mL) once every 8–12wks.|
|ranibizumab||Lucentis||6mg/mL (0.3mg), 10mg/mL (0.5mg)||soln for intravitreal inj||0.3mg (0.05mL of 6mg/mL) once a month (approx. 28 days)|
|Cimerli*||6mg/mL (0.3mg), 10mg/mL (0.5mg)||soln for intravitreal inj|
|VEGF INHIBITOR + ANGIOPOIETIN-2 (ANG-2) INHIBITOR|
|faricimab-svoa||Vabysmo||120mg/mL||soln for intravitreal inj||Regimen 1: 6mg (0.05mL) once every 4wks for at least 4 doses, then may be adjusted by up to 4-week interval increments or reductions of up to 8-week interval increments based on CST and visual acuity evaluations through week 52; or
Regimen 2: 6mg (0.05mL) once every 4wks for the 1st 6 doses, followed by 6mg (0.05mL) every 8wks over the next 28wks.
|VEGF INHIBITOR + HUMAN IgG1|
|aflibercept||Eylea||2mg/0.05mL||soln for intravitreal inj||2mg (0.05mL) once every 4wks (approx. 28 days, monthly) for the 1st 5 doses, followed by 2mg (0.05mL) once every 8wks (2mos); some may need the monthly dosing after the 1st 5mos|
|dexamethasone||Ozurdex||0.7mg||intravitreal implant||One implant in each affected eye(s)|
|fluocinolone acetonide||Iluvien||0.19mg||intravitreal implant||One implant in each affected eye(s)†|
* Biosimilar to Lucentis.
† One implant is designed to release fluocinolone at an initial rate of 0.25mcg/day lasting 36mos.
Not an inclusive list of medications and/or official indications. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling.